Problems in hemophilia therapy

Research output: Contribution to journalArticlepeer-review


At present, the future of patients with hemophilia A may be regarded with more optimism due to advances in diagnosis and management which have occurred in recent years. However, a number of problems are still unresolved and others are now emerging against this optimistic background. The development of an inhibitor specifically destroying factor VIII coagulant activity renders the management at best difficult. It has been recognized recently that multitransfused hemophiliacs have a high incidence of abnormal liver function tests, and there is preliminary evidence that these are the expression of chronic active liver disease. This review is focused on these pitfalls of hemophilia care and emphasizes the recent developments in these fields and their impact on the pattern of life of hemophiliacs.

Original languageEnglish
Pages (from-to)301-311
Number of pages11
JournalLa Ricerca in Clinica e in Laboratorio
Issue number4
Publication statusPublished - Oct 1981


  • Chronic liver disease
  • Factor VIII inhibitors
  • Hemophilia therapy
  • Prothrombin complex concentrates

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Problems in hemophilia therapy'. Together they form a unique fingerprint.

Cite this